BMS Faces Phase III Setback for Camzyos in Non-Obstructive HCM Study
US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has reported a setback in the Phase...
Drug
Beijing Wantai Launches Phase III Trial for 9-Valent HPV Vaccine in Chinese Males
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has initiated a Phase III...
Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA₂ Inhibitor for Alzheimer’s Disease
China-based Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) has announced the initiation of a Phase...
Hengrui Pharmaceuticals Gains NMPA Clearance for Phase II Study of HRS-7058 in Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced clearance from the National Medical...
Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its...
Roche’s Columvi Approved by EC for Relapsed DLBCL Treatment in Europe
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that it has received marketing...
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-1819 in Allergic Rhinitis Study
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received approval...
CSPC Pharmaceutical Gains FDA Approval for SYS6041 ADC in Advanced Solid Tumors
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical...
HighTide Therapeutics’ HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment
China-based HighTide Therapeutics Inc. (HKG: 2511) has announced positive results from two Phase III clinical...
Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259
China-based Zhuhai Beihai Biotech Co., Ltd. has announced that it has received clinical trial clearance...
MSD’s Gardasil 9 Approved in China for Males Aged 16 to 26
US pharmaceutical major Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced marketing approval from...
Bristol-Myers Squibb Wins FDA Approval for Opdivo-Yervoy Combo in First-Line HCC Treatment
Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another indication approval from the US Food and...
Zhaoke Ophthalmology Launches Phase II Study for Brimochol PF in Presbyopia Treatment
Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the initiation of a multi-center, double-blinded, crossover, placebo-controlled...
CSPC Pharmaceutical Gains NMPA Approval for Clinical Trial of SYH2046 in Heart Failure
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
Amgen’s Imdelltra Shows Positive Phase III Results in Small Cell Lung Cancer
US biotech giant Amgen (NASDAQ: AMGN) has announced positive results from the global Phase III...
Jiangsu Hengrui Secures NMPA Approval for Clinical Trials of SHR-3792 and HRS-9190
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received separate...
Johnson & Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an...
Tasly Pharma Gains NMPA Green Light for CAR-T Therapy Clinical Study in Recurrent Glioblastoma
China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received approval from...
CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin
China-based CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294) has announced that it has received...
Juventas Cell Therapy Secures China Clinical Trial Approval for Inaticabtagene Autoleucel in AIHA
Chinese firm Juventas Cell Therapy Ltd has obtained tacit clinical trial approval in China for...